Schizophrenie-Studie findet neuen Biomarker und Medikamentenkandidaten zur Behandlung kognitiver Symptome: „Eine große Studie wurde an menschlichen Gehirn-Rückenmarks-Flüssigkeits- und Mausmodellen durchgeführt.“ »
https://news.northwestern.edu/stories/2026/03/schizophrenia-study-finds-new-biomarker-drug-candidate-to-treat-cognitive-symptoms
3 Kommentare
>A lot of people with schizophrenia cannot integrate well into society because of these cognitive deficits. Our discovery could solve these challenges by establishing the basis of a revolutionary and completely novel treatment strategy through a tandem biomarker-peptide therapeutic approach.
Reference: Dos Santos M et al., Soluble α2δ-1, altered in disease CSF, modulates network homeostasis and rescues deficits in a neuropsychiatric mouse model, Neuron, Online March 19, 2026. DOI: 10.1016/j.neuron.2026.02.004. https://www.cell.com/neuron/abstract/S0896-6273(26)00087-5
The real question is, can this treat Negative Symptoms. I, for example, have Avolition. So far there really isn’t anything I can do about it.
A new schizophrenia drug is always welcome, we’ve had a couple new ones in the last 5 years, but they all really treat the same Positive Symptoms that have been treated for years. Again, having more medications is good because maybe these will work for some people who weren’t able to be treated via other medications, but the real serious breakthrough in this type of medication would be helping to alleviate things like Anhedonia and Avolition.